Skip to main content

Table 1 Patient demographics and number of icatibant-treated attacks

From: Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Characteristic Underweight BMI Normal BMI Overweight BMI Obese BMI
Patients, n (%) 12 (3.5) 153 (44.7) 119 (34.8) 58 (17.0)
BMI (kg/m2)a     
 Mean ± SD 18.0 ± 0.5 22.2 ± 1.8 26.9 ± 1.3 34.5 ± 4.1
 Median (range) 18.1 (16.7–18.4) 22.4 (18.7–25.0) 26.6 (25.0–29.8) 33.3 (30.0–46.7)
Sex, n (%)     
 Female 11 (91.7) 105 (68.6) 60 (50.4) 33 (56.9)
 Male 1 (8.3) 48 (31.4) 59 (49.6) 25 (43.1)
Age at enrollment (years), n (%)
 ≥ 12 to < 18 1 (8.3) 2 (1.3) 1 (0.8) 0
 ≥ 18 to < 30 8 (66.7) 53 (34.6) 24 (20.2) 10 (17.2)
 ≥ 30 to < 50 1 (8.3) 66 (43.1) 52 (43.7) 27 (46.6)
 ≥ 50 to < 65 1 (8.3) 27 (17.6) 30 (25.2) 16 (27.6)
 ≥ 65 1 (8.3) 5 (3.3) 12 (10.1) 5 (8.6)
Country, n (%)
 Austria 0 6 (3.9) 3 (2.5) 0
 Brazil 0 6 (3.9) 7 (5.9) 3 (5.2)
 Denmark 0 0 1 (0.8) 2 (3.4)
 France 2 (16.7) 45 (29.4) 21 (17.6) 8 (13.8)
 Germany 2 (16.7) 16 (10.5) 16 (13.4) 12 (20.7)
 Greece 0 3 (2.0) 3 (2.5) 1 (1.7)
 Israel 2 (16.7) 20 (13.1) 15 (12.6) 6 (10.3)
 Italy 1 (8.3) 18 (11.8) 14 (11.8) 4 (6.9)
 Spain 4 (33.3) 20 (13.1) 22 (18.5) 8 (13.8)
 Sweden 0 0 1 (0.8) 0
 United Kingdom 1 (8.3) 19 (12.4) 16 (13.4) 14 (24.1)
Ongoing long-term prophylaxis, n (%)
 n 3 75 58 33
 C1-INHb 0 11 (14.7) 11 (19.0) 4 (12.1)
 Attenuated androgensb 0 47 (62.7) 44 (75.9) 24 (72.7)
 Tranexamic acidb 2 (66.7) 24 (32.0) 9 (15.5) 11 (33.3)
 Otherb 1 (33.3) 8 (10.7) 4 (6.9) 3 (9.1)
No. of icatibant-treated attacks during enrollment 104 1314 829 450
No. of icatibant-treated attacks per patientc     
 Mean ± SD 8.7 ± 13.5 8.6 ± 14.8 7.0 ± 11.3 7.8 ± 10.8
 Median (range) 4.0 (1–47) 4.0 (1–101) 3.0 (1–83) 3.5 (1–57)
  1. BMI body mass index; C1-INH C1-inhibitor; SD standard deviation
  2. aAt study entry
  3. bPercentage calculated from number of patients using long-term prophylaxis at study entry and/or during enrollment
  4. cAttack rate during enrollment. P = 0.469 comparing the normal, overweight, and obese categories. The underweight category was excluded from the comparison due to small sample size. Two patients (one normal BMI, one obese BMI) were found to be outliers because of an abnormally high rate of reinjections and rescue medication use. When their data are excluded, mean ± SD for normal = 8.4 ± 14.6 attacks/patient and for obese = 6.9 ± 8.6 attacks/patient (Additional file 1: Table S1)